The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer

References

• Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002; 94(10):2766-92; PMID:12173348; http://dx.doi.org/10.1002/cncr.10593
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J clin oncol 2007; 25(35):5570-7; PMID:18065729; http://dx.doi.org/10.1200/JCO.2007.12.5435
   PubMed Web of Science ®Google Scholar
• Werner CA. The Older Population: 2010. The 2010 Census Briefs 2011.
   Google Scholar
• van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, Prokop M, Habbema JD, Oudkerk M, van Klaveren RJ. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007; 120(4):868-74; PMID:17131307; http://dx.doi.org/10.1002/ijc.22134
   PubMedGoogle Scholar
• National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365(5):395-409; PMID:21714641; http://dx.doi.org/10.1056/NEJMoa1102873
   PubMed Web of Science ®Google Scholar
• National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, et al. The national lung screening trial: overview and study design. Radiology 2011; 258(1):243-53; PMID:21045183; http://dx.doi.org/10.1148/radiol.10091808
   PubMed Web of Science ®Google Scholar
• Sacher AG, Le LW, Leighl NB, Coate LE. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC? J Thorac Oncol 2013; 8(3):366-8; PMID:23407560; http://dx.doi.org/10.1097/JTO.0b013e31827e2145
   PubMed Web of Science ®Google Scholar
• Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J clin oncol 2012; 30(17):2036-8; PMID:22547597; http://dx.doi.org/10.1200/JCO.2012.41.6727
   PubMed Web of Science ®Google Scholar
• Pallis AG, Ring A, Fortpied C, Penninckx B, Van Nes MC, Wedding U, Vonminckwitz G, Johnson CD, Wyld L, Timmer-Bonte A, et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Ann Oncol 2011; 22(8):1922-6; PMID:21266517; http://dx.doi.org/10.1093/annonc/mdq687
   PubMedGoogle Scholar
• Dorshkind K, Montecino-Rodriguez E, Signer RA. The ageing immune system: is it ever too old to become young again? Nat Rev Immunol 2009; 9(1):57-62; PMID:19104499; http://dx.doi.org/10.1038/nri2471
   PubMed Web of Science ®Google Scholar
• Naylor K, Li G, Vallejo AN, Lee WW, Koetz K, Bryl E, Witkowski J, Fulbright J, Weyand CM, Goronzy JJ. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174(11):7446-52; PMID:15905594; http://dx.doi.org/10.4049/jimmunol.174.11.7446
   PubMed Web of Science ®Google Scholar
• Pawelec G, Derhovanessian E, Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hematol 2010; 75(2):165-72; PMID:20656212; http://dx.doi.org/10.1016/j.critrevonc.2010.06.012
   PubMedGoogle Scholar
• Ruby CE, Weinberg AD. OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol 2009; 182(3):1481-9; PMID:19155495; http://dx.doi.org/10.4049/jimmunol.182.3.1481
   PubMed Web of Science ®Google Scholar
• Provinciali M, Argentati K, Tibaldi A. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 2000; 7(7):624-32; PMID:10819579; http://dx.doi.org/10.1038/sj.gt.3301131
   PubMedGoogle Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313(5795):1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29(6):610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353(25):2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348(3):203-13; PMID:12529460; http://dx.doi.org/10.1056/NEJMoa020177
   PubMed Web of Science ®Google Scholar
• Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29(15):1949-55; PMID:21483002; http://dx.doi.org/10.1200/JCO.2010.30.5037
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis WD, Sadelain M, Adusumilli PS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3CD3 ratio are independent predictors of recurrence. J Clin Oncol 2013; 31(4):490-8; PMID:23269987; http://dx.doi.org/10.1200/JCO.2012.45.2052
   PubMedGoogle Scholar
• Bograd AJ, Suzuki K, Vertes E, Colovos C, Morales EA, Sadelain M, Adusumilli PS. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011; 60(11):1509-27; PMID:21913025; http://dx.doi.org/10.1007/s00262-011-1103-6
   PubMed Web of Science ®Google Scholar
• Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 2011; 17(16):5247-56; PMID:21659461; http://dx.doi.org/10.1158/1078-0432.CCR-10-2805
   PubMedGoogle Scholar
• Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, Travis WD, Adusumilli PS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011; 60(12):1721-8; PMID:21769693; http://dx.doi.org/10.1007/s00262-011-1073-8
   PubMedGoogle Scholar
• Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S, Katoh H. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89(9):1736-42; PMID:14583778; http://dx.doi.org/10.1038/sj.bjc.6601331
   PubMed Web of Science ®Google Scholar
• Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H, Nishimura M. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94(11):1003-9; PMID:14611679; http://dx.doi.org/10.1111/j.1349-7006.2003.tb01392.x
   PubMed Web of Science ®Google Scholar
• Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010; 5(5):585-90; PMID:20234320
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137(4):1270-9; PMID:19577568; http://dx.doi.org/10.1053/j.gastro.2009.06.053
   PubMed Web of Science ®Google Scholar
• Ng R, de Boer R, Green MD. Undertreatment of elderly patients with non-small-cell lung cancer. Clin Lung Cancer 2005; 7(3):168-74; PMID:16354310; http://dx.doi.org/10.3816/CLC.2005.n.031
   PubMedGoogle Scholar
• Sawada S, Komori E, Nogami N, Bessho A, Segawa Y, Shinkai T, Nakata M, Yamashita M. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition. Chest 2005; 128(3):1557-63; PMID:16162758; http://dx.doi.org/10.1378/chest.128.3.1557
   PubMedGoogle Scholar
• Blanchard EM, Arnaoutakis K, Hesketh PJ. Lung cancer in octogenarians. J Thorac Oncol 2010; 5(6):909-16; PMID:20521358; http://dx.doi.org/10.1097/JTO.0b013e3181d89b48
   PubMedGoogle Scholar
• Goodgame B, Viswanathan A, Zoole J, Gao F, Miller CR, Subramanian J, Meyers BF, Patterson AG, Govindan R. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. J Thorac Oncol 2009; 4(11):1370-4; PMID:19692932; http://dx.doi.org/10.1097/JTO.0b013e3181b6bc1b
   PubMedGoogle Scholar
• Hanagiri T, Muranaka H, Hashimoto M, Nagashima A, Yasumoto K. Results of surgical treatment of lung cancer in octogenarians. Lung Cancer 1999; 23(2):129-33; PMID:10217616; http://dx.doi.org/10.1016/S0169-5002(99)00006-9
   PubMedGoogle Scholar
• Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291(22):2720-6; PMID:15187053; http://dx.doi.org/10.1001/jama.291.22.2720
   PubMed Web of Science ®Google Scholar
• Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006; 36(4):216-20; PMID:16640737; http://dx.doi.org/10.1111/j.1445-5994.2006.01033.x
   PubMed Web of Science ®Google Scholar
• Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Res 2013; 73(8):2381-8; PMID:23580578; http://dx.doi.org/10.1158/0008-5472.CAN-12-3932
   PubMed Web of Science ®Google Scholar
• Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005; 23(35):8959-67; PMID:16219934; http://dx.doi.org/10.1200/JCO.2005.01.4910
   PubMed Web of Science ®Google Scholar
• Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC cancer 2010; 10:112; PMID:20338029; http://dx.doi.org/10.1186/1471-2407-10-112
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang T, Ye J, Li H, Huang J, Li X, Wu B, Huang X, Hou J. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012; 61(10):1849-56; PMID:22456757; http://dx.doi.org/10.1007/s00262-012-1231-7
   PubMedGoogle Scholar
• Rusch VW, Appelman HD., Blackstone E. AJCC Cancer Staging Manual, 7th edition edn, New York, NY: Springer; 2009.
   Google Scholar
• Sarkaria IS, Zakowski MF, Pham D, Pham D, Hezel M, Ebright MI, Chuai S, Venkatraman ES, Kris MG, Rusch VW, Singh B. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. Ann Thorac Surg 2008; 85(1):216-23; PMID:18154814; http://dx.doi.org/10.1016/j.athoracsur.2007.07.046
   PubMedGoogle Scholar
• Kadota K, Bograd A, Nitadori J, Cherkassky L, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Prognostic impact of tumor-infiltrating immune cells in lung squamous cell carcinoma. J Thorac Oncol. 2013; 8(Supple 2):S378.
   Web of Science ®Google Scholar
• Chappell R. Competing risk analyses: how are they different and why should you care? Clin Cancer Res 2012; 18(8):2127-9; PMID:22427347; http://dx.doi.org/10.1158/1078-0432.CCR-12-0455
   PubMed Web of Science ®Google Scholar
• Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res 2012; 18(8):2301-8; PMID:22282466; http://dx.doi.org/10.1158/1078-0432.CCR-11-2097
   PubMed Web of Science ®Google Scholar
• Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16(3):1141-54; http://dx.doi.org/10.1214/aos/1176350951
   Web of Science ®Google Scholar